
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9223894/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Multiple Sclerosis Journal, 2022, 28, 801-816.	3.0	26
2	Propagating Uncertainty Across Cascaded Medical Imaging Tasks for Improved Deep Learning Inference. IEEE Transactions on Medical Imaging, 2022, 41, 360-373.	8.9	12
3	Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN. Multiple Sclerosis and Related Disorders, 2022, 57, 103367.	2.0	2
4	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. Neurology, 2022, 98, .	1.1	15
5	How patients with multiple sclerosis acquire disability. Brain, 2022, 145, 3147-3161.	7.6	126
6	Patterns of white and gray structural abnormality associated with paediatric demyelinating disorders. Neurolmage: Clinical, 2022, 34, 103001.	2.7	0
7	Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the PhaseÂ3 EVOLVE-MS-1 Study. Advances in Therapy, 2022, 39, 1810-1831.	2.9	16
8	Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology, 2022, 13, 852563.	4.8	18
9	Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies. Frontiers in Neurology, 2022, 13, 809273.	2.4	2
10	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal, 2022, 28, 1526-1540.	3.0	16
11	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. Multiple Sclerosis Journal, 2022, 28, 1591-1605.	3.0	19
12	Progressive retinal changes in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 61, 103761.	2.0	2
13	Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation. Brain, 2022, 145, 2008-2017.	7.6	5
14	Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. Multiple Sclerosis Journal, 2022, 28, 1697-1709.	3.0	12
15	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104.	3.6	7
16	Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Multiple Sclerosis Journal, 2022, 28, 1927-1936.	3.0	10
17	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal, 2022, 28, 1944-1962.	3.0	16
18	Chronic lesion activity and disability progression in secondary progressive multiple sclerosis. BMJ Neurology Open, 2022, 4, e000240.	1.6	12

#	Article	IF	CITATIONS
19	Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. Multiple Sclerosis Journal, 2021, 27, 1497-1505.	3.0	23
20	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	3.0	5
21	Silent New Brain MRI Lesions in Children with MOGâ€Antibody Associated Disease. Annals of Neurology, 2021, 89, 408-413.	5.3	33
22	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Multiple Sclerosis and Related Disorders, 2021, 48, 102673.	2.0	20
23	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 48.	9.0	11
24	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098213.	3.5	30
25	Cohort Bias Adaptation in Aggregated Datasets for Lesion Segmentation. Lecture Notes in Computer Science, 2021, , 101-111.	1.3	0
26	Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation. Multiple Sclerosis Journal, 2021, 27, 2062-2076.	3.0	25
27	Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise. Brain Communications, 2021, 3, fcab176.	3.3	13
28	Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098794.	3.5	4
29	Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1948-1959.	3.0	9
30	Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nature Communications, 2021, 12, 2078.	12.8	112
31	Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 995-1006.	1.9	20
32	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders, 2021, 51, 102844.	2.0	19
33	Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, 378-388.	1.1	100
34	Slowly expanding lesions are a marker of progressive MS – No. Multiple Sclerosis Journal, 2021, 27, 1681-1683.	3.0	9
35	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 729-738.	10.2	89
36	Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103149.	2.0	3

#	Article	IF	CITATIONS
37	Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes. JAMA Network Open, 2021, 4, e2128871.	5.9	27
38	Assessing the differential sensitivities of wave-CAIPI ViSTa myelin water fraction and magnetization transfer saturation for efficiently quantifying tissue damage in MS. Multiple Sclerosis and Related Disorders, 2021, 56, 103309.	2.0	4
39	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 1001-1011.	10.2	36
40	Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study. Child Neuropsychology, 2021, , 1-22.	1.3	0
41	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Annals of Clinical and Translational Neurology, 2021, 8, 2252-2269.	3.7	34
42	Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurology, 2020, 77, 82.	9.0	213
43	Exploring uncertainty measures in deep networks for Multiple sclerosis lesion detection and segmentation. Medical Image Analysis, 2020, 59, 101557.	11.6	216
44	Factors associated with health care utilization in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 38, 101511.	2.0	7
45	Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis Journal, 2020, 26, 1729-1739.	3.0	41
46	Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies. Neurolmage, 2020, 208, 116442.	4.2	17
47	Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. BMJ Open, 2020, 10, e038861.	1.9	16
48	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	10.2	64
49	Five years of ocrelizumab in relapsing multiple sclerosis. Neurology, 2020, 95, e1854-e1867.	1.1	81
50	Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology, 2020, 95, 436-444.	1.1	100
51	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 998-1009.	10.2	98
52	Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions. American Journal of Neuroradiology, 2020, 41, 1584-1591.	2.4	19
53	Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CÓNFIRM, and ENDORSE. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642091500.	3.5	47
54	CNN Detection of New and Enlarging Multiple Sclerosis Lesions from Longitudinal Mri Using Subtraction Images. , 2020, , .		12

#	Article	IF	CITATIONS
55	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurology, 2020, 77, 1132.	9.0	245
56	Brain volume loss in individuals over time: Source of variance and limits of detectability. NeuroImage, 2020, 214, 116737.	4.2	11
57	Increased mental health care use by mothers of children with multiple sclerosis. Neurology, 2020, 94, e1040-e1050.	1.1	10
58	Automated separation of diffusely abnormal white matter from focal white matter lesions on MRI in multiple sclerosis. NeuroImage, 2020, 213, 116690.	4.2	11
59	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG <i>MS</i> study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 483-492.	1.9	26
60	Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 767-775.	3.7	20
61	Saliency Based Deep Neural Network for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI. Lecture Notes in Computer Science, 2020, , 108-118.	1.3	2
62	Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI. Multiple Sclerosis Journal, 2019, 25, 980-986.	3.0	11
63	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262.	3.0	37
64	Local Indicators of Spatial Autocorrelation (LISA): Application to Blind Noise-Based Perceptual Quality Metric Index for Magnetic Resonance Images. Journal of Imaging, 2019, 5, 20.	3.0	4
65	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 845-856.	10.2	110
66	Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain, 2019, 142, 2787-2799.	7.6	136
67	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020.	10.2	191
68	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033.	10.2	184
69	Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI. American Journal of Neuroradiology, 2019, 40, 1162-1169.	2.4	34
70	White matter plasticity and maturation in human cognition. Glia, 2019, 67, 2020-2037.	4.9	31
71	High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study. PLoS ONE, 2019, 14, e0218215.	2.5	15
72	Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. New England Journal of Medicine, 2019, 380, 2406-2417.	27.0	219

#	Article	IF	CITATIONS
73	Effect of dimethyl fumarate on lymphocytes in RRMS. Neurology, 2019, 92, e1724-e1738.	1.1	66
74	A surfaceâ€in gradient of thalamic damage evolves in pediatric multiple sclerosis. Annals of Neurology, 2019, 85, 340-351.	5.3	42
75	Imaging outcome measures of neuroprotection and repair in MS. Neurology, 2019, 92, 519-533.	1.1	53
76	CNN Prediction of Future Disease Activity for Multiple Sclerosis Patients from Baseline MRI and Lesion Labels. Lecture Notes in Computer Science, 2019, , 57-69.	1.3	4
77	Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. Brain, 2019, 142, 617-632.	7.6	72
78	056â€Efficacy and safety of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A18.2-A19.	1.9	1
79	High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e598.	6.0	50
80	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis Journal, 2019, 25, 1915-1925.	3.0	122
81	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis Journal, 2019, 25, 1605-1617.	3.0	57
82	Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurements. Neurolmage, 2019, 184, 555-565.	4.2	45
83	The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. Multiple Sclerosis Journal, 2019, 25, 515-522.	3.0	32
84	Propagating Uncertainty Across Cascaded Medical Imaging Tasks for Improved Deep Learning Inference. Lecture Notes in Computer Science, 2019, , 23-32.	1.3	5
85	MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. The Lancet Child and Adolescent Health, 2018, 2, 191-204.	5.6	86
86	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	1.0	32
87	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
88	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	10.2	238
89	Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1055-1066.	3.0	14
90	Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1605-1616.	3.0	26

#	Article	IF	CITATIONS
91	Standardized quality metric system for structural brain magnetic resonance images in multi-center neuroimaging study. BMC Medical Imaging, 2018, 18, 31.	2.7	2
92	Incidence and prevalence of MS in children. Neurology, 2018, 91, e1579-e1590.	1.1	26
93	Improving the SIENA performance using BEaST brain extraction. PLoS ONE, 2018, 13, e0196945.	2.5	6
94	Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e499.	6.0	4
95	Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879508.	3.5	6
96	Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879114.	3.5	16
97	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 1017-1027.	27.0	237
98	Image Quality Evaluation in Clinical Research: A Case Study on Brain and Cardiac MRI Images in Multi-Center Clinical Trials. IEEE Journal of Translational Engineering in Health and Medicine, 2018, 6, 1-15.	3.7	7
99	Phase IV study of retention on fingolimod <i>versus</i> injectable multiple sclerosis therapies: a randomized clinical trial. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877433.	3.5	22
100	Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters. BioMedical Engineering OnLine, 2018, 17, 76.	2.7	14
101	Lesion Detection, Segmentation and Prediction in Multiple Sclerosis Clinical Trials. Lecture Notes in Computer Science, 2018, , 15-28.	1.3	6
102	Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 420-431.	3.0	33
103	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple Sclerosis Journal, 2017, 23, 253-265.	3.0	126
104	High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology, 2017, 88, 842-852.	1.1	128
105	Statistical power and prediction accuracy in multisite resting-state fMRI connectivity. NeuroImage, 2017, 149, 220-232.	4.2	78
106	Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial. BMC Neurology, 2017, 17, 29.	1.8	24
107	Bayesian framework inspired no-reference region-of-interest quality measure for brain MRI images. Journal of Medical Imaging, 2017, 4, 025504.	1.5	7
108	White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. Brain, 2017, 140, 1300-1315.	7.6	52

#	Article	IF	CITATIONS
109	Monophasic demyelination reduces brain growth in children. Neurology, 2017, 88, 1744-1750.	1.1	43
110	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	27.0	1,322
111	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	27.0	1,324
112	The spatial statistics of structural magnetic resonance images: application to post-acquisition quality assessment of brain MRI images. Imaging Science Journal, 2017, 65, 468-483.	0.5	5
113	Predicting Future Disease Activity and Treatment Responders for Multiple Sclerosis Patients Using a Bag-of-Lesions Brain Representation. Lecture Notes in Computer Science, 2017, , 186-194.	1.3	7
114	Alemtuzumab CARE-MS I 5-year follow-up. Neurology, 2017, 89, 1107-1116.	1.1	188
115	Alemtuzumab CARE-MS II 5-year follow-up. Neurology, 2017, 89, 1117-1126.	1.1	232
116	Noâ€reference quality measure in brain MRI images using binary operations, texture and set analysis. IET Image Processing, 2017, 11, 672-684.	2.5	16
117	MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis. Neurology, 2017, 89, 714-721.	1.1	16
118	Application of calibrated fMRI in Alzheimer's disease. NeuroImage: Clinical, 2017, 15, 348-358.	2.7	48
119	Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study. Journal of Neurology, 2017, 264, 1728-1734.	3.6	2
120	ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 686-695.	3.0	47
121	Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. Journal of Neurology, 2017, 264, 304-315.	3.6	86
122	A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731774309.	1.0	25
123	Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731667664.	1.0	7
124	Cognitive and Behavioral Functioning in Childhood Acquired Demyelinating Syndromes. Journal of the International Neuropsychological Society, 2016, 22, 1050-1060.	1.8	7
125	MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. Neurology, 2016, 87, 905-911.	1.1	16
126	MRI in the evaluation of pediatric multiple sclerosis. Neurology, 2016, 87, S88-96.	1.1	42

#	Article	IF	CITATIONS
127	Subgroup and sensitivity analyses of annualized relapse rate over 2Âyears in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis. Journal of Neurology, 2016, 263, 1778-1787.	3.6	11
128	Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2016, 15, 1148-1159.	10.2	52
129	Delineation of cortical pathology in multiple sclerosis using multi-surface magnetization transfer ratio imaging. Neurolmage: Clinical, 2016, 12, 858-868.	2.7	7
130	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon $\hat{l}^2$ -1a in MS. Neurology, 2016, 87, 1464-1472.	1.1	28
131	Longitudinal change in Paced Auditory Serial Addition Test (PASAT) performance following immunoablative therapy and haematopoietic stem cell transplant in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	2
132	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet, The, 2016, 388, 576-585.	13.7	296
133	Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731663411.	1.0	10
134	Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 35-46.	10.2	158
135	Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease. Multiple Sclerosis Journal, 2016, 22, 1266-1278.	3.0	21
136	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 373-381.	10.2	150
137	Intracortical inhibition abnormality during the remission phase of multiple sclerosis is related to upper limb dexterity and lesions. Clinical Neurophysiology, 2016, 127, 1503-1511.	1.5	23
138	Altered resting-state functional connectivity in cognitively preserved pediatric-onset MS patients and relationship to structural damage and cognitive performance. Multiple Sclerosis Journal, 2016, 22, 792-800.	3.0	20
139	Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis Journal, 2016, 22, 599-607.	3.0	38
140	Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Multiple Sclerosis Journal, 2016, 22, 385-388.	3.0	50
141	Adaptive multi-level conditional random fields for detection and segmentation of small enhanced pathology in medical images. Medical Image Analysis, 2016, 27, 17-30.	11.6	25
142	Efficacy of delayedâ€release dimethyl fumarate in relapsingâ€remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology, 2015, 2, 103-118.	3.7	48
143	Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis. Clinical Neuropharmacology, 2015, 38, 127-131.	0.7	9
144	Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731558977.	1.0	6

DOUGLAS L ARNOLD

#	Article	IF	CITATIONS
145	Non-Local Means Inpainting of MS Lesions in Longitudinal Image Processing. Frontiers in Neuroscience, 2015, 9, 456.	2.8	19
146	Rotation-invariant multi-contrast non-local means for MS lesion segmentation. NeuroImage: Clinical, 2015, 8, 376-389.	2.7	56
147	Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations. NeuroImage, 2015, 118, 126-132.	4.2	96
148	Temporal Hierarchical Adaptive Texture CRF for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI. IEEE Transactions on Medical Imaging, 2015, 34, 1227-1241.	8.9	17
149	Probabilistic Multiple Sclerosis Lesion Classification Based on Modeling Regional Intensity Variability and Local Neighborhood Information. IEEE Transactions on Biomedical Engineering, 2015, 62, 1281-1292.	4.2	26
150	IMaGe: Iterative Multilevel Probabilistic Graphical Model for Detection and Segmentation of Multiple Sclerosis Lesions in Brain MRI. Lecture Notes in Computer Science, 2015, 24, 514-526.	1.3	17
151	Quantitative Measurement of tissue damage and recovery within new T2w lesions in pediatric- and adult-onset multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 718-725.	3.0	16
152	Towards a better understanding of <i>pseudoatrophy</i> in the brain of multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 675-676.	3.0	64
153	High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS). JAMA Neurology, 2015, 72, 159.	9.0	158
154	Normalization of White Matter Intensity on T1â€Weighted Images of Patients with Acquired Central Nervous System Demyelination. Journal of Neuroimaging, 2015, 25, 184-190.	2.0	11
155	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2015, 373, 1418-1428.	27.0	245
156	Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis. Neurology, 2015, 85, 1663-1669.	1.1	62
157	Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Multiple Sclerosis Journal, 2015, 21, 1025-1035.	3.0	91
158	Is It Possible to Differentiate the Impact of Pediatric Monophasic Demyelinating Disorders and Multiple Sclerosis After a First Episode of Demyelination?. Lecture Notes in Computer Science, 2015, , 38-48.	1.3	1
159	Quantitative Determination of Regional Lesion Volume and Distribution in Children and Adults with Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2014, 9, e85741.	2.5	64
160	Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth. Neurology, 2014, 83, 2140-2146.	1.1	107
161	Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology, 2014, 83, 2219-2226.	1.1	58
162	Reply. Annals of Neurology, 2014, 75, 463-464.	5.3	0

#	Article	IF	CITATIONS
163	Surface-based analysis reveals regions of reduced cortical magnetization transfer ratio in patients with multiple sclerosis: A proposed method for imaging subpial demyelination. Human Brain Mapping, 2014, 35, 3402-3413.	3.6	41
164	Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurology, 2014, 14, 240.	1.8	40
165	Magnetization transfer ratio recovery in new lesions decreases during adolescence in pediatric-onset multiple sclerosis patients. NeuroImage: Clinical, 2014, 6, 237-242.	2.7	26
166	Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Annals of Neurology, 2014, 75, 43-49.	5.3	240
167	Brain Volume and Fatigue in Patients With Postpoliomyelitis Syndrome. PM and R, 2014, 6, 215-220.	1.6	5
168	Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. NeuroImage: Clinical, 2014, 4, 10-17.	2.7	73
169	Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology, The, 2014, 13, 657-665.	10.2	339
170	Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. Journal of Neurology, 2014, 261, 2429-2437.	3.6	37
171	Imaging of repeated episodes of demyelination and remyelination in multiple sclerosis. NeuroImage: Clinical, 2014, 6, 20-25.	2.7	46
172	Fourâ€neighborhood clique kernel: A general framework for Bayesian and variational techniques of noise reduction in magnetic resonance images of the brain. International Journal of Imaging Systems and Technology, 2014, 24, 224-238.	4.1	0
173	Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. Journal of Neurology, 2014, 261, 1794-1802.	3.6	69
174	Optimal selection of regularization parameter in total variation method for reducing noise in magnetic resonance images of the brain. Biomedical Engineering Letters, 2014, 4, 80-92.	4.1	5
175	Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies. NeuroImage: Clinical, 2014, 6, 166-170.	2.7	71
176	Quality of life outcomes with BC-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study. Multiple Sclerosis Journal, 2014, 20, 243-252.	3.0	51
177	A Generative Model for Automatic Detection of Resolving Multiple Sclerosis Lesions. Lecture Notes in Computer Science, 2014, , 118-129.	1.3	5
178	Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. Journal of Neurology, 2013, 260, 1901-1906.	3.6	30
179	Temporally Consistent Probabilistic Detection of New Multiple Sclerosis Lesions in Brain MRI. IEEE Transactions on Medical Imaging, 2013, 32, 1490-1503.	8.9	56
180	Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging. Medical Image Analysis, 2013, 17, 1-18.	11.6	280

# ARTICLE IF CITATIONS Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after 181 hematopoietic stem cell transplantation. Annals of Neurology, 2013, 73, 341-354. Imaging of Demyelination and Remyelination in Multiple Sclerosis., 2013, 233-253. 182 4 Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: 3.6 subgroup analyses of the DEFINE study. Journal of Neurology, 2013, 260, 2297-2305. Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and 184 4.2 56 remyelination in multiple sclerosis. NeuroImage, 2013, 66, 103-109. Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology, 2013, 80, 246-252. 1.1 79 Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. 186 1.1 31 Neurology, 2013, 81, 1215-1221. Masquerades of Acquired Demyelination in Children. Journal of Child Neurology, 2013, 28, 184-197. 1.4 The clique potential of Markov random field in a random experiment for estimation of noise levels in 188 4.1 5 2D brain MRI. International Journal of Imaging Systems and Technology, 2013, 23, 304-313. Changes in cognitive performance over a 1-year period in children and adolescents with multiple 1.3 sclerosis.. Neuropsychology, 2013, 27, 210-219. Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations. Canadian 190 0.5 178 Journal of Neurological Sciences, 2013, 40, 307-323. Adaptive Voxel, Texture and Temporal Conditional Random Fields for Detection of Gad-Enhancing 1.3 Multiple Sclerosis Lesions in Brain MRI. Lecture Notes in Computer Science, 2013, 16, 543-550. Memory Performance and Normalized Regional Brain Volumes in Patients with Pediatric-Onset 192 1.8 24 Multiple Sclerosis. Journal of the International Neuropsychological Society, 2012, 18, 471-480. Large, Nonplateauing Relationship Between Clinical Disability and Cerebral White Matter Lesion Load 4.5 24 in Patients With Multiple Sclerosis. Archives of Neurology, 2012, 69, 89. Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI Using 194 8.9 38 Conditional Random Fields. IEEE Transactions on Medical Imaging, 2012, 31, 1181-1194. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting 1,041 multiple sclerosis: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1819-1828. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a 196 13.7 1,040 randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1829-1839. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Annals of Neurology, 2012, 72, 5.3 117 211-223. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal 198 27.0 1,493 of Medicine, 2012, 367, 1098-1107.

**DOUGLAS L ARNOLD** 

#	Article	IF	CITATIONS
199	Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?. Acta Neuropathologica, 2012, 123, 627-638.	7.7	176
200	Hierarchical Conditional Random Fields for Detection of Gad-Enhancing Lesions in Multiple Sclerosis. Lecture Notes in Computer Science, 2012, 15, 379-386.	1.3	4
201	Axonal pathology in patients with multiple sclerosis. , 2011, , 150-164.		1
202	Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurology, The, 2011, 10, 436-445.	10.2	267
203	MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurology, The, 2011, 10, 1065-1073.	10.2	159
204	Trimmed-Likelihood Estimation for Focal Lesions and Tissue Segmentation in Multisequence MRI for Multiple Sclerosis. IEEE Transactions on Medical Imaging, 2011, 30, 1455-1467.	8.9	62
205	Phase III doseâ€comparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology, 2011, 69, 75-82.	5.3	65
206	Evaluating intensity normalization on MRIs of human brain with multiple sclerosis. Medical Image Analysis, 2011, 15, 267-282.	11.6	126
207	Reproducibility of quantitative magnetizationâ€transfer imaging parameters from repeated measurements. Magnetic Resonance in Medicine, 2010, 64, 391-400.	3.0	27
208	Robust Rician noise estimation for MR images. Medical Image Analysis, 2010, 14, 483-493.	11.6	200
209	Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis. NeuroImage, 2010, 52, 1261-1267.	4.2	82
210	Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies. Biology of Blood and Marrow Transplantation, 2010, 16, 1076-1083.	2.0	46
211	Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume change. NeuroImage, 2010, 49, 1601-1611.	4.2	68
212	Improved Precision in the Measurement of Longitudinal Global and Regional Volumetric Changes via a Novel MRI Gradient Distortion Characterization and Correction Technique. Lecture Notes in Computer Science, 2010, , 324-333.	1.3	15
213	Detection of Gad-Enhancing Lesions in Multiple Sclerosis Using Conditional Random Fields. Lecture Notes in Computer Science, 2010, 13, 41-48.	1.3	8
214	Path Sampling to Compute Integrated Likelihoods: An Adaptive Approach. Journal of Computational and Graphical Statistics, 2009, 18, 415-437.	1.7	2
215	Defining Multiple Sclerosis Treatment Response With Magnetic Resonance Imaging. Archives of Neurology, 2009, 66, 19.	4.5	8
216	Measuring Demyelination and Remyelination in Acute Multiple Sclerosis Lesion Voxels. Archives of Neurology, 2009, 66, 375-81.	4.5	51

#	Article	IF	CITATIONS
217	Fatigue in Postâ€poliomyelitis Syndrome: Association With Diseaseâ€Related, Behavioral, and Psychosocial Factors. PM and R, 2009, 1, 442-449.	1.6	27
218	1H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 72-79.	0.6	22
219	The Metabolic Epicenter of Supratentorial Gliomas: A <sup>1</sup> H-MRSI Study. Canadian Journal of Neurological Sciences, 2009, 36, 696-706.	0.5	4
220	Multiple Sclerosis Lesion Segmentation Using an Automatic Multimodal Graph Cuts. Lecture Notes in Computer Science, 2009, 12, 584-591.	1.3	21
221	Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. Journal of Neuro-Oncology, 2008, 90, 63-76.	2.9	21
222	Automated quality control of brain MR images. Journal of Magnetic Resonance Imaging, 2008, 28, 308-319.	3.4	54
223	Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Annals of Neurology, 2008, 63, 254-262.	5.3	169
224	Lesion distribution in children with clinically isolated syndromes. Annals of Neurology, 2008, 63, 401-405.	5.3	75
225	Rituximab in relapsingâ€remitting multiple sclerosis: A 72â€week, openâ€label, phase I trial. Annals of Neurology, 2008, 63, 395-400.	5.3	484
226	Elevated serum inflammatory markers in post-poliomyelitis syndrome. Journal of the Neurological Sciences, 2008, 271, 80-86.	0.6	34
227	B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis. New England Journal of Medicine, 2008, 358, 676-688.	27.0	2,107
228	Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis. Current Opinion in Neurology, 2008, 21, 272-277.	3.6	21
229	Evidence for neuroprotection and remyelination using imaging techniques. Neurology, 2007, 68, S83-S90.	1.1	19
230	Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial. Archives of Neurology, 2007, 64, 1407.	4.5	159
231	The place of MRI in monitoring the individual MS patient. Journal of the Neurological Sciences, 2007, 259, 123-127.	0.6	4
232	The search for the missing links in multiple sclerosis. Current Neurology and Neuroscience Reports, 2007, 7, 93-94.	4.2	1
233	Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter. NeuroImage, 2006, 29, 637-642.	4.2	59
234	Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. Journal of Neurology, 2006, 253, 1060-1063.	3.6	49

#	Article	IF	CITATIONS
235	Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. Journal of Neuroimmunology, 2006, 176, 198-215.	2.3	80
236	Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurology, The, 2005, 4, 74-75.	10.2	7
237	The role of edema and demyelination in chronic T1 black holes: A quantitative magnetization transfer study. Journal of Magnetic Resonance Imaging, 2005, 21, 103-110.	3.4	55
238	Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: Consensus report of the white matter study group. Journal of Magnetic Resonance Imaging, 2005, 21, 669-675.	3.4	43
239	Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways. Journal of Neurology, 2005, 252, v25-v29.	3.6	16
240	Interferon Beta Promotes Nerve Growth Factor Secretion Early in the Course of Multiple Sclerosis. Archives of Neurology, 2005, 62, 563.	4.5	87
241	1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain, 2005, 128, 2483-2506.	7.6	94
242	A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of avonex in patients with multiple sclerosis. Clinical Therapeutics, 2004, 26, 511-521.	2.5	31
243	The Relationship Between Diffuse Axonal Damage and Fatigue in Multiple Sclerosis. Archives of Neurology, 2004, 61, 201.	4.5	181
244	Axonal Damage in Multiple Sclerosis Patients with High versus Low Expanded Disability Status Scale Score. Canadian Journal of Neurological Sciences, 2004, 31, 225-228.	0.5	21
245	Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. Journal of Neurology, 2003, 250, 924-931.	3.6	54
246	Entorhinal Cortex MRI Assessment in Temporal, Extratemporal, and Idiopathic Generalized Epilepsy. Epilepsia, 2003, 44, 1070-1074.	5.1	52
247	Automated detection of focal cortical dysplasia lesions using computational models of their MRI characteristics and texture analysis. NeuroImage, 2003, 19, 1748-1759.	4.2	125
248	Proton Magnetic Resonance Spectroscopic Imaging Can Predict Length of Survival in Patients with Supratentorial Gliomas. Neurosurgery, 2003, 53, 565-576.	1.1	64
249	Chapter 10 Magnetic Resonance Imaging and Spectroscopy: Insights into the Pathology and Pathophysiology of Multiple Sclerosis. Blue Books of Practical Neurology, 2003, 27, 139-167.	0.1	2
250	Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. American Journal of Neuroradiology, 2003, 24, 476-80.	2.4	40
251	The Lesions of Multiple Sclerosis. New England Journal of Medicine, 2002, 346, 199-200.	27.0	23
252	Diffuse Axonal and Tissue Injury in Patients With Multiple Sclerosis With Low Cerebral Lesion Load and No Disability. Archives of Neurology, 2002, 59, 1565.	4.5	176

#	Article	IF	CITATIONS
253	Windows on the working brain: magnetic resonance spectroscopy. , 2002, , 146-159.		0
254	Chapter 54 MRS for imaging neuronal dysfunction in epilepsy. Supplements To Clinical Neurophysiology, 2002, , 359-364.	2.1	0
255	Computational Models of MRI Characteristics of Focal Cortical Dysplasia Improve Lesion Detection. NeuroImage, 2002, 17, 1755-1760.	4.2	67
256	Magnetization transfer can predict clinical evolution in patients with multiple sclerosis. Journal of Neurology, 2002, 249, 662-668.	3.6	102
257	Magnetic Resonance Spectroscopy in Epilepsy: Clinical Issues. Epilepsia, 2002, 43, 32-39.	5.1	28
258	MRI in the diagnosis and management of multiple sclerosis. Neurology, 2002, 58, S23-31.	1.1	71
259	Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution. Current Opinion in Neurology, 2001, 14, 279-287.	3.6	46
260	Axonal metabolic recovery in multiple sclerosis patients treated with interferon β-1b. Journal of Neurology, 2001, 248, 979-986.	3.6	171
261	N-acetylaspartate: Usefulness as an indicator of viable neuronal tissue. Annals of Neurology, 2001, 50, 823-823.	5.3	35
262	Texture analysis and morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy. Annals of Neurology, 2001, 49, 770-775.	5.3	156
263	Aerobic conditioning in patients with mitochondrial myopathies: Physiological, biochemical, and genetic effects. Annals of Neurology, 2001, 50, 133-141.	5.3	191
264	Evidence of Axonal Damage in the Early Stages of Multiple Sclerosis and Its Relevance to Disability. Archives of Neurology, 2001, 58, 65-70.	4.5	439
265	Texture analysis and morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extraâ€ŧemporal partial epilepsy. Annals of Neurology, 2001, 49, 770-775.	5.3	6
266	Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle and Nerve, 2000, 23, 1316-1334.	2.2	100
267	Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree. Annals of Neurology, 2000, 47, 179-185.	5.3	125
268	Proton Magnetic Resonance Spectroscopic Imaging Studies in Patients with Newly Diagnosed Partial Epilepsy. Epilepsia, 2000, 41, 825-831.	5.1	21
269	Lateralization of Temporal Lobe Epilepsy (TLE) and Discrimination of TLE from Extra-TLE Using Pattern Analysis of Magnetic Resonance Spectroscopic and Volumetric Data. Epilepsia, 2000, 41, 832-842.	5.1	25
270	Using Proton Magnetic Resonance Spectroscopic Imaging to Predict in Vivo the Response of Recurrent Malignant Gliomas to Tamoxifen Chemotherapy. Neurosurgery, 2000, 46, 306-317.	1.1	68

#	Article	IF	CITATIONS
271	Multiple Sclerosis: Magnetization Transfer MR Imaging of White Matter before Lesion Appearance on T2-weighted Images. Radiology, 2000, 215, 824-830.	7.3	174
272	Is Ictal Recording Mandatory in Temporal Lobe Epilepsy?. Archives of Neurology, 2000, 57, 497.	4.5	93
273	Neuronal dysfunction in children with newly diagnosed temporal lobe epilepsy. Pediatric Neurology, 2000, 22, 281-286.	2.1	13
274	T2 Relaxometry Can Lateralize Mesial Temporal Lobe Epilepsy in Patients with Normal MRI. NeuroImage, 2000, 12, 739-746.	4.2	129
275	MR SPECTROSCOPY AND MR IMAGING IN METABOLIC MYOPATHIES. Neurologic Clinics, 2000, 18, 35-52.	1.8	32
276	Morphometric MRI Analysis of the Parahippocampal Region in Temporal Lobe Epilepsy. Annals of the New York Academy of Sciences, 2000, 911, 495-500.	3.8	61
277	In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain, 1999, 122, 1933-1939.	7.6	176
278	Proton Magnetic Resonance Spectroscopy for the Diagnosis and Management of Cerebral Disorders. Archives of Neurology, 1999, 56, 919.	4.5	149
279	Relation of Interictal Spike Frequency to 1H-MRSI-Measured NAA/Cr. Epilepsia, 1999, 40, 1821-1827.	5.1	21
280	Neuroimaging evidence of progressive neuronal loss and dysfunction in temporal lobe epilepsy. Annals of Neurology, 1999, 45, 568-576.	5.3	260
281	Proton Magnetic Resonance Spectroscopic Imaging in Patients with Extratemporal Epilepsy. Epilepsia, 1998, 39, 267-273.	5.1	65
282	In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using1H magnetic resonance spectroscopic imaging. Annals of Neurology, 1998, 44, 273-278.	5.3	78
283	Intracellular phosphates in inclusion body myositis?A 31P magnetic resonance spectroscopy study. , 1998, 21, 1523-1525.		26
284	Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. NeuroReport, 1998, 9, 1757-1761.	1.2	179
285	Magnetic Resonance Spectroscopy Guided Brain Tumor Resection: Differentiation Between Recurrent Glioma and Radiation Change in Two Diagnostically Difficult Cases. Canadian Journal of Neurological Sciences, 1998, 25, 13-22.	0.5	108
286	Function and organization in dysgenic cortex. Journal of Neurosurgery, 1997, 87, 113-121.	1.6	76
287	Proton magnetic resonance spectroscopic imaging for discrimination of absence and complex partial seizures. Annals of Neurology, 1997, 41, 74-81.	5.3	68
288	Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: A series of 100 patients. Annals of Neurology, 1997, 42, 737-746.	5.3	225

#	Article	IF	CITATIONS
289	ADP Recovery After a Brief Ischemic Exercise in Normal and Diseased Human Muscle — a31P MRS Study. , 1996, 9, 165-172.		66
290	Impairment of muscle mitochondrial oxidative metabolism in McArdle's disease. , 1996, 19, 764-769.		48
291	Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nature Medicine, 1996, 2, 323-325.	30.7	522
292	Mitochondrial Disease. Chest, 1995, 108, 182-189.	0.8	53
293	Imaging of axonal damage in vivo in Rasmussen's syndrome. Brain, 1995, 118, 753-758.	7.6	52
294	Late-onset mitochondrial myopathy. Annals of Neurology, 1995, 37, 16-23.	5.3	139
295	Chemical pathology of acute demyelinating lesions and its correlation with disability. Annals of Neurology, 1995, 38, 901-909.	5.3	288
296	Reversible decreases in <i>N</i> â€acetylaspartate after acute brain injury. Magnetic Resonance in Medicine, 1995, 34, 721-727.	3.0	453
297	Proton magnetic resonance spectroscopic images and MRI volumetric studies for lateralization of temporal lobe epilepsy. Magnetic Resonance Imaging, 1995, 13, 1187-1191.	1.8	40
298	Familial myopathy with conspicuous depletion of mitochondria in muscle fibers: a morphologically distinct disease. Neuromuscular Disorders, 1995, 5, 139-144.	0.6	13
299	Glutaric acidemia type II: Neuroimaging and spectroscopy evidence for developmental encephalomyopathy. Pediatric Neurology, 1995, 12, 350-353.	2.1	21
300	Association of cerebral dysgenesis and lactic acidemia with X-linked PDH E1α subunit mutations in females. Pediatric Neurology, 1995, 13, 327-332.	2.1	17
301	Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images. Annals of Neurology, 1994, 35, 211-216.	5.3	221
302	Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Annals of Neurology, 1994, 36, 76-82.	5.3	192
303	Magnetic resonance spectroscopy in niemann-pick disease type C: Correlation with diagnosis and clinical response to cholestyramine and lovastatin. Pediatric Neurology, 1994, 10, 228-232.	2.1	49
304	Cerebral dysgenesis and lactic acidemia: An MRI/MRS phenotype associated with pyruvate dehydrogenase deficiency. Pediatric Neurology, 1994, 11, 224-229.	2.1	80
305	Differential Diagnosis of Human Intracranial Tumors in Vivo Using 1H Mr Spectroscopic Imaging and Feature Space for Spectral Pattern Recognition. , 1994, , 299-313.		1
306	Evidence for mitochondrial dysfunction in patients with alternating hemiplegia of childhood. Annals of Neurology, 1993, 33, 604-607.	5.3	36

DOUGLAS L ARNOLD

#	Article	IF	CITATIONS
307	Myoblast transfer in duchenne muscular dystrophy. Annals of Neurology, 1993, 34, 8-17.	5.3	291
308	Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Annals of Neurology, 1992, 31, 235-241.	5.3	311
309	1H NMR characterization of normal human cerebrospinal fluid and the detection of methylmalonic acid in a vitamin B12 deficient patient. NMR in Biomedicine, 1991, 4, 192-200.	2.8	36
310	Characterization of astrocytomas, meningiomas, and pituitary adenomas by phosphorus magnetic resonance spectroscopy. Journal of Neurosurgery, 1991, 74, 447-453.	1.6	45
311	Proton magnetic resonance spectroscopy of human brainin vivo in the evaluation of multiple sclerosis: Assessment of the load of disease. Magnetic Resonance in Medicine, 1990, 14, 154-159.	3.0	275
312	A proton magnetic resonance spectroscopy study of focal epilepsy in humans. Neurology, 1990, 40, 985-985.	1.1	134
313	Early Metabolic Changes Following Chemotherapy of Human Gliomas In Vivo Demonstrated by Phosphorus Magnetic Resonance Spectroscopy. Investigative Radiology, 1989, 24, 958-961.	6.2	25
314	Letters to the editor. Muscle and Nerve, 1987, 10, 183-184.	2.2	2
315	Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Biochemical Society Transactions, 1985, 13, 654-654.	3.4	14
316	Evobrutinib reduces volume of slowly expanding lesions. , 0, , .		0